| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasma Cells | 2 | 2019 | 196 | 1.190 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2019 | 204 | 1.150 |
Why?
|
| Immunophenotyping | 25 | 2017 | 1726 | 1.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 11 | 2019 | 2475 | 1.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2018 | 840 | 1.000 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2019 | 460 | 0.980 |
Why?
|
| Bone Marrow | 12 | 2019 | 2437 | 0.930 |
Why?
|
| Translocation, Genetic | 9 | 2017 | 1285 | 0.920 |
Why?
|
| Myelodysplastic Syndromes | 10 | 2019 | 3149 | 0.870 |
Why?
|
| Blast Crisis | 2 | 2018 | 587 | 0.680 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 2019 | 7259 | 0.630 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2019 | 413 | 0.590 |
Why?
|
| Chromosomes, Human, Pair 14 | 6 | 2015 | 287 | 0.570 |
Why?
|
| Azathioprine | 1 | 2016 | 73 | 0.540 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2016 | 32 | 0.540 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 314 | 0.500 |
Why?
|
| Flow Cytometry | 16 | 2015 | 3037 | 0.490 |
Why?
|
| In Situ Hybridization, Fluorescence | 11 | 2019 | 2308 | 0.490 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2016 | 460 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2011 | 156 | 0.450 |
Why?
|
| Karyotyping | 8 | 2019 | 1063 | 0.430 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2018 | 2616 | 0.420 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 678 | 0.400 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 554 | 0.390 |
Why?
|
| Mastocytosis, Systemic | 2 | 2013 | 119 | 0.390 |
Why?
|
| Genes, myc | 2 | 2016 | 372 | 0.390 |
Why?
|
| Immunocompromised Host | 1 | 2016 | 718 | 0.390 |
Why?
|
| Dendritic Cells | 1 | 2018 | 1110 | 0.380 |
Why?
|
| Mast Cells | 2 | 2013 | 217 | 0.370 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 1427 | 0.340 |
Why?
|
| Cell Differentiation | 2 | 2019 | 4104 | 0.330 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2009 | 67 | 0.320 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2015 | 2895 | 0.310 |
Why?
|
| DNA-Binding Proteins | 3 | 2018 | 5000 | 0.300 |
Why?
|
| Mutation | 10 | 2018 | 15900 | 0.300 |
Why?
|
| World Health Organization | 1 | 2008 | 327 | 0.280 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2016 | 1737 | 0.280 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1387 | 0.280 |
Why?
|
| Biopsy | 6 | 2019 | 3384 | 0.260 |
Why?
|
| Leukemia, B-Cell | 1 | 2006 | 114 | 0.260 |
Why?
|
| Aged | 31 | 2019 | 73127 | 0.250 |
Why?
|
| Chromosome Inversion | 2 | 2005 | 197 | 0.250 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 1423 | 0.240 |
Why?
|
| Middle Aged | 36 | 2019 | 90030 | 0.240 |
Why?
|
| CD2 Antigens | 1 | 2004 | 30 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2005 | 257 | 0.230 |
Why?
|
| Male | 39 | 2019 | 127917 | 0.230 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 2281 | 0.230 |
Why?
|
| DNA Nucleotidylexotransferase | 2 | 2000 | 56 | 0.220 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2011 | 796 | 0.220 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 2663 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 2172 | 0.210 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2002 | 88 | 0.210 |
Why?
|
| Aged, 80 and over | 13 | 2019 | 30923 | 0.210 |
Why?
|
| Gene Amplification | 2 | 2016 | 766 | 0.200 |
Why?
|
| Immunohistochemistry | 7 | 2018 | 7632 | 0.200 |
Why?
|
| Adult | 32 | 2019 | 81689 | 0.200 |
Why?
|
| Biomarkers, Tumor | 8 | 2018 | 10695 | 0.190 |
Why?
|
| Humans | 55 | 2019 | 270033 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 3602 | 0.190 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2017 | 1143 | 0.180 |
Why?
|
| Plasma Exchange | 1 | 2002 | 104 | 0.180 |
Why?
|
| Female | 37 | 2019 | 148486 | 0.180 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2004 | 441 | 0.180 |
Why?
|
| Antigens, CD | 3 | 2008 | 1411 | 0.180 |
Why?
|
| Leukemia, Biphenotypic, Acute | 2 | 2016 | 49 | 0.170 |
Why?
|
| Dioxygenases | 2 | 2018 | 173 | 0.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2003 | 1066 | 0.160 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2010 | 240 | 0.160 |
Why?
|
| Antigens, Neoplasm | 2 | 2008 | 1580 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 4 | 2011 | 1456 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4814 | 0.160 |
Why?
|
| Myeloproliferative Disorders | 2 | 2017 | 881 | 0.150 |
Why?
|
| Neoplasm Proteins | 4 | 2010 | 3343 | 0.150 |
Why?
|
| Bone Marrow Cells | 5 | 2017 | 965 | 0.150 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 993 | 0.150 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2017 | 50 | 0.140 |
Why?
|
| Kidney Tubules | 1 | 2016 | 124 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 3 | 2013 | 928 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2017 | 2633 | 0.130 |
Why?
|
| Diagnosis, Differential | 5 | 2016 | 4819 | 0.130 |
Why?
|
| Primary Myelofibrosis | 2 | 2015 | 913 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2012 | 513 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2015 | 119 | 0.120 |
Why?
|
| Antigens, CD20 | 2 | 2008 | 207 | 0.120 |
Why?
|
| Calreticulin | 1 | 2015 | 87 | 0.120 |
Why?
|
| Genes, p53 | 1 | 2019 | 1140 | 0.120 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2014 | 9 | 0.120 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 2 | 2011 | 103 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2016 | 252 | 0.110 |
Why?
|
| Young Adult | 5 | 2019 | 22134 | 0.110 |
Why?
|
| Receptors, IgE | 2 | 2002 | 43 | 0.100 |
Why?
|
| Chromosome Banding | 2 | 2016 | 280 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 433 | 0.100 |
Why?
|
| Polycythemia | 1 | 2012 | 65 | 0.100 |
Why?
|
| Philadelphia Chromosome | 1 | 2016 | 845 | 0.100 |
Why?
|
| Antigens, CD34 | 3 | 2004 | 637 | 0.100 |
Why?
|
| Receptors, CXCR | 1 | 2010 | 12 | 0.090 |
Why?
|
| Lymphocytosis | 1 | 2011 | 55 | 0.090 |
Why?
|
| Cell Size | 1 | 2011 | 137 | 0.090 |
Why?
|
| Thiazoles | 1 | 2015 | 723 | 0.090 |
Why?
|
| Stem Cell Factor | 2 | 2008 | 83 | 0.090 |
Why?
|
| Complementarity Determining Regions | 1 | 2010 | 44 | 0.090 |
Why?
|
| Receptors, Chemokine | 1 | 2010 | 112 | 0.090 |
Why?
|
| Janus Kinase 2 | 1 | 2015 | 754 | 0.090 |
Why?
|
| Apoptosis | 2 | 2016 | 7741 | 0.090 |
Why?
|
| Receptors, Virus | 1 | 2010 | 153 | 0.090 |
Why?
|
| Blotting, Southern | 2 | 2009 | 451 | 0.090 |
Why?
|
| Phenotype | 3 | 2016 | 6485 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2353 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 4 | 2009 | 1755 | 0.090 |
Why?
|
| Chromosome Aberrations | 2 | 2016 | 2031 | 0.080 |
Why?
|
| Cisplatin | 1 | 2016 | 2497 | 0.080 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2009 | 41 | 0.080 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2009 | 37 | 0.080 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2010 | 174 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 758 | 0.080 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2008 | 9 | 0.080 |
Why?
|
| Tryptases | 1 | 2008 | 45 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2009 | 188 | 0.080 |
Why?
|
| Diabetic Neuropathies | 1 | 2009 | 92 | 0.080 |
Why?
|
| Basophils | 1 | 2008 | 43 | 0.080 |
Why?
|
| Leukemia | 3 | 2004 | 1719 | 0.070 |
Why?
|
| Lymphocyte Count | 1 | 2009 | 485 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2013 | 484 | 0.070 |
Why?
|
| Pentostatin | 2 | 2006 | 121 | 0.070 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2004 | 749 | 0.070 |
Why?
|
| CD5 Antigens | 3 | 2004 | 129 | 0.070 |
Why?
|
| Cell Lineage | 3 | 2013 | 692 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2019 | 9464 | 0.070 |
Why?
|
| Leukemia, T-Cell | 1 | 2006 | 90 | 0.070 |
Why?
|
| Prognosis | 7 | 2018 | 22451 | 0.070 |
Why?
|
| Leukemia, Lymphoid | 1 | 2006 | 289 | 0.070 |
Why?
|
| Myosin Heavy Chains | 1 | 2005 | 117 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 3468 | 0.060 |
Why?
|
| Graft vs Host Disease | 3 | 2001 | 2808 | 0.060 |
Why?
|
| RNA Precursors | 1 | 2004 | 125 | 0.060 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2003 | 56 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2003 | 189 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 3653 | 0.050 |
Why?
|
| Mitochondria | 2 | 2016 | 1296 | 0.050 |
Why?
|
| Annexin A5 | 1 | 2002 | 74 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2015 | 3662 | 0.050 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2002 | 144 | 0.050 |
Why?
|
| CD56 Antigen | 1 | 2002 | 85 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2014 | 2357 | 0.050 |
Why?
|
| Leukemic Infiltration | 1 | 2002 | 73 | 0.050 |
Why?
|
| Centrifugation | 1 | 2002 | 65 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 1985 | 581 | 0.050 |
Why?
|
| Lymphocytes | 2 | 2004 | 1272 | 0.050 |
Why?
|
| Aminoglycosides | 1 | 2002 | 233 | 0.050 |
Why?
|
| Hematocrit | 1 | 2002 | 151 | 0.050 |
Why?
|
| Leukapheresis | 1 | 2002 | 166 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1948 | 0.050 |
Why?
|
| Splenic Neoplasms | 1 | 2002 | 124 | 0.050 |
Why?
|
| Membrane Potentials | 1 | 2002 | 442 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2009 | 2100 | 0.050 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 72 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2000 | 183 | 0.050 |
Why?
|
| Bone Marrow Examination | 1 | 2000 | 150 | 0.050 |
Why?
|
| Burkitt Lymphoma | 2 | 2000 | 348 | 0.040 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2000 | 47 | 0.040 |
Why?
|
| Peroxidase | 1 | 2000 | 132 | 0.040 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2000 | 67 | 0.040 |
Why?
|
| Lymphoma, T-Cell | 1 | 2003 | 366 | 0.040 |
Why?
|
| Immunotoxins | 2 | 2002 | 120 | 0.040 |
Why?
|
| Safety | 1 | 2002 | 461 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2003 | 742 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 10382 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2002 | 453 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 9039 | 0.040 |
Why?
|
| Disease-Free Survival | 5 | 2018 | 10258 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 4958 | 0.040 |
Why?
|
| Blood Cell Count | 2 | 2016 | 233 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2448 | 0.040 |
Why?
|
| Survival Analysis | 6 | 2016 | 9288 | 0.040 |
Why?
|
| Acute Disease | 2 | 2002 | 2489 | 0.040 |
Why?
|
| Biomarkers | 3 | 2017 | 5046 | 0.040 |
Why?
|
| Lymphoma, Follicular | 1 | 2003 | 636 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2002 | 778 | 0.040 |
Why?
|
| Equipment Design | 1 | 2002 | 1199 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 1376 | 0.040 |
Why?
|
| JC Virus | 1 | 1997 | 47 | 0.040 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1997 | 45 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 3437 | 0.040 |
Why?
|
| Remission Induction | 2 | 2018 | 3648 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2002 | 671 | 0.040 |
Why?
|
| Adolescent | 9 | 2008 | 32647 | 0.040 |
Why?
|
| Organelle Biogenesis | 1 | 2016 | 31 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 126 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 4 | 2006 | 4463 | 0.030 |
Why?
|
| Treatment Outcome | 8 | 2017 | 33691 | 0.030 |
Why?
|
| Time Factors | 4 | 2016 | 12953 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1997 | 247 | 0.030 |
Why?
|
| Ricin | 1 | 1995 | 38 | 0.030 |
Why?
|
| Antigens, CD7 | 1 | 1995 | 30 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 472 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2016 | 303 | 0.030 |
Why?
|
| Mercaptopurine | 2 | 2008 | 130 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 1365 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 425 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2017 | 39736 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2000 | 1742 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2015 | 203 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6254 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1997 | 889 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 4887 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2015 | 329 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 693 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2001 | 7009 | 0.030 |
Why?
|
| Vincristine | 3 | 2008 | 1581 | 0.030 |
Why?
|
| Melanoma | 1 | 2010 | 5594 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 288 | 0.030 |
Why?
|
| Abnormal Karyotype | 1 | 2013 | 101 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2002 | 6204 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2016 | 5658 | 0.030 |
Why?
|
| Dexamethasone | 3 | 2008 | 1507 | 0.030 |
Why?
|
| Prednisone | 2 | 2008 | 1031 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2006 | 5434 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2018 | 16640 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2358 | 0.030 |
Why?
|
| Methotrexate | 2 | 2008 | 1025 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 5773 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 812 | 0.020 |
Why?
|
| Clone Cells | 1 | 2013 | 587 | 0.020 |
Why?
|
| Dasatinib | 1 | 2015 | 881 | 0.020 |
Why?
|
| Receptors, CXCR6 | 1 | 2010 | 13 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2002 | 3070 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 1425 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2010 | 40 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2016 | 997 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 3939 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2002 | 13378 | 0.020 |
Why?
|
| Doxorubicin | 3 | 2008 | 3142 | 0.020 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2010 | 104 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 1145 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 2008 | 3242 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2010 | 168 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2016 | 6368 | 0.020 |
Why?
|
| Vasa Nervorum | 1 | 2009 | 2 | 0.020 |
Why?
|
| Child | 4 | 2008 | 30466 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2010 | 179 | 0.020 |
Why?
|
| Age Factors | 2 | 2013 | 5449 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 1942 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2009 | 239 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2004 | 16987 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 1997 | 999 | 0.020 |
Why?
|
| Cytogenetics | 2 | 2003 | 152 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2027 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2010 | 317 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 5757 | 0.020 |
Why?
|
| Survival Rate | 3 | 2013 | 12508 | 0.020 |
Why?
|
| DNA, Neoplasm | 2 | 2009 | 1957 | 0.020 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2008 | 36 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 1555 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 9040 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 341 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 15172 | 0.020 |
Why?
|
| Risk Factors | 4 | 2014 | 17824 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 1987 | 188 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 5694 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1987 | 284 | 0.020 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 14615 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2008 | 322 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2002 | 770 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2006 | 213 | 0.020 |
Why?
|
| Histocompatibility Testing | 2 | 1999 | 486 | 0.020 |
Why?
|
| Freezing | 1 | 1985 | 62 | 0.020 |
Why?
|
| Leukocyte Transfusion | 1 | 1985 | 44 | 0.020 |
Why?
|
| Animals | 4 | 2016 | 61714 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 6840 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 273 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2006 | 292 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 7038 | 0.020 |
Why?
|
| Factor VIII | 1 | 1985 | 64 | 0.020 |
Why?
|
| Transfusion Reaction | 1 | 1985 | 101 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2009 | 935 | 0.020 |
Why?
|
| Platelet Transfusion | 1 | 1985 | 166 | 0.020 |
Why?
|
| Granulocytes | 1 | 1985 | 244 | 0.020 |
Why?
|
| Plasma | 1 | 1985 | 146 | 0.010 |
Why?
|
| HLA Antigens | 2 | 1999 | 593 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1985 | 212 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 5153 | 0.010 |
Why?
|
| CD13 Antigens | 1 | 2004 | 43 | 0.010 |
Why?
|
| Interphase | 1 | 2003 | 155 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 1985 | 205 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2003 | 64 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 7343 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2006 | 3398 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2004 | 6182 | 0.010 |
Why?
|
| Antibodies | 2 | 1996 | 806 | 0.010 |
Why?
|
| Megakaryocytes | 1 | 2003 | 129 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 119 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 4043 | 0.010 |
Why?
|
| Lasers | 1 | 2003 | 235 | 0.010 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2002 | 95 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2002 | 152 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2003 | 301 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2004 | 589 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2002 | 253 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2003 | 622 | 0.010 |
Why?
|
| Incidence | 2 | 2002 | 5806 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 628 | 0.010 |
Why?
|
| Vidarabine | 1 | 2006 | 1383 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2002 | 415 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2003 | 437 | 0.010 |
Why?
|
| Daunorubicin | 1 | 2002 | 314 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2009 | 1716 | 0.010 |
Why?
|
| Cytarabine | 2 | 2002 | 2013 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 245 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 2004 | 584 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2003 | 668 | 0.010 |
Why?
|
| Myeloid Cells | 1 | 2002 | 271 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 5309 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 6499 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 1405 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 835 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 1110 | 0.010 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2000 | 75 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 5099 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 1008 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2000 | 119 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 573 | 0.010 |
Why?
|
| Neoplasms | 1 | 1985 | 15902 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2002 | 501 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2000 | 270 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 1937 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 108 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2001 | 1808 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 3588 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 723 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 693 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 1039 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 1900 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 14832 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1997 | 753 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 16183 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 5061 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 3046 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1995 | 320 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 2116 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 3630 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 4944 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1995 | 483 | 0.010 |
Why?
|
| Recurrence | 1 | 2001 | 4872 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 3041 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 4118 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 2651 | 0.010 |
Why?
|
| Neurons | 1 | 2002 | 2453 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1996 | 1105 | 0.010 |
Why?
|
| Carmustine | 1 | 1990 | 224 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 3161 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 35465 | 0.010 |
Why?
|
| Oncogenes | 1 | 1993 | 700 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1995 | 4318 | 0.000 |
Why?
|
| Immunologic Techniques | 1 | 1987 | 43 | 0.000 |
Why?
|
| Etoposide | 1 | 1990 | 905 | 0.000 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1987 | 171 | 0.000 |
Why?
|
| Hematologic Tests | 1 | 1987 | 84 | 0.000 |
Why?
|
| Cytokines | 1 | 1996 | 2810 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1987 | 591 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 7892 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1990 | 3842 | 0.000 |
Why?
|